Anti Inflammatory News and Research

RSS

Gene therapy for rheumatoid arthritis: promising results

Researchers have reported the first clinical evidence that gene therapy reduces symptoms in patients with rheumatoid arthritis, an important milestone for this promising treatment which has endured a sometimes turbulent past.

27 Jan 2009

Lisofylline drug improves type 2 insulin action; reduces harm of fat in preclinical study

Results of a preclinical study involving DiaKine Therapeutics' lead drug candidate Lisofylline (LSF) indicate the compound may reduce two key risk factors for type 2 diabetes.

23 Jan 2009

Tanning beds provide potential pain relief for fibromyalgia patients

Ultraviolet light may help relieve pain in fibromyalgia syndrome patients, according to a preliminary study at Wake Forest University Baptist Medical Center conducted by dermatology, rheumatology, and public health sciences researchers.

19 Jan 2009

Discovery of better treatment for bacterial pneumonia

Scientists at St. Jude Children's Research Hospital have demonstrated a more effective treatment for bacterial pneumonia following influenza.

9 Jan 2009

Nitric oxide monitoring does not help most children with asthma

The level of nitric oxide (NO) in an asthmatic's exhaled breath can portend worsening asthma symptoms, and may even signify an imminent attack linked to underlying airway inflammation.

7 Jan 2009

Onyx Pharmaceuticals acquires license option on novel JAK2 inhibitors from S*BIO

Onyx Pharmaceuticals, Inc. has announced that it has acquired an option to license rights to SB1518, an orally available, potent, and selective inhibitor of Janus Kinase 2 (JAK2), and SB1578, also a JAK2 inhibitor, from S*BIO Pte Ltd based in Singapore.

6 Jan 2009

New online tool for calculating colorectal cancer risk

A new online tool for calculating colorectal cancer risk in men and women age 50 or older was launched today, based on a new risk-assessment model developed by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health.

1 Jan 2009

First U.S. implants of Embozene color-advanced microspheres embolization technology

Against the backdrop of a flagging economy, bailouts, and bleak predictions, there is a biotechnology firm in suburban Atlanta with a future as bright as New Year's Eve fireworks.

1 Jan 2009

Acute gastric injury due to high-dose analgesics?

Analgesics, NSAIDs and acetaminophen, are commonly used for the relief of fever, headaches, and other minor aches and pains.

30 Dec 2008

Carbon monoxide used to protect mouse nerve cells from damage

Researchers at Johns Hopkins have shown that brain damage was reduced by as much as 62.2 percent in mice who inhale low amounts of carbon monoxide after an induced stroke.

15 Dec 2008

GlaxoSmithKline statement on FDA advisory committee vote on use of asthma medicines containing long-acting beta agonists

The following is GlaxoSmithKline's statement regarding recommendations of a combined Advisory Committee to the FDA on the use of asthma medicines containing long-acting beta agonists, including GSK's Serevent (salmeterol) and Advair (salmeterol/fluticasone proprionate).

14 Dec 2008

New class of anti-inflammatory drugs

In the treatment of pain, inflammation and fever, non-steroid anti-rheumatic drugs (NSAR) such as acetylsalicylic acid - more commonly known as Aspirin - or Ibuprofen have always been popular choices.

10 Dec 2008

Pycnogenol reduces inflammatory marker C-reactive protein in osteoarthritis

Osteoarthritis (OA), a type of arthritis caused by the breakdown and loss of cartilage, affects more than 20 million Americans.

10 Dec 2008

Study sheds light on inflammatory bowel disease

Scientists have uncovered vital clues about how to treat serious bowel disorders by studying the behaviour of cells in the colon.

8 Dec 2008

ISTA Pharmaceuticals announces trial results for topical Xibrom 0.09%

ISTA Pharmaceuticals, Inc. has announced results from the Company's recently completed Phase III clinical program of Xibrom (0.09% bromfenac sodium ophthalmic solution) QD (once-daily).

8 Dec 2008

FDA advisory committee to dscuss PMA for Genzyme's Synvisc-One

Genzyme Corporation has announced that its Premarket Approval (PMA) application supplement for Synvisc-One (hylan G-F 20) will be discussed this Tuesday, December 9th, at a public meeting of the FDA's Orthopaedic and Rehabilitation Devices Advisory Committee in Gaithersburg, Maryland.

8 Dec 2008